Drug-induced phospholipidosis: issues and future directions - Wikidata - awgldk - TriplyDB

Drug-induced phospholipidosis: issues and future directions

Drug-induced phospholipidosis: issues and future directions

http://www.wikidata.org/entity/Q28246047

about

Molecular imaging of intracellular drug-membrane aggregate formation Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities Identification of drugs inducing phospholipidosis by novel in vitro data New insights into the intracellular distribution pattern of cationic amphiphilic drugs.Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates Physicochemical drug properties associated with in vivo toxicological outcomes: a review.Proceedings of the 2015 National Toxicology Program Satellite Symposium.A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis Ultrastructural analysis in preclinical safety evaluation.Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.Mechanisms of amine accumulation in, and egress from, lysosomes.Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383 In vitro assays and biomarkers for drug-induced phospholipidosis.Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake.Screening for the drug-phospholipid interaction: correlation to phospholipidosis.Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.Pathology and Neurotoxicity in Dogs after Repeat Dose Exposure to a Serotonin 5-HT1B Inhibitor Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system.Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review.A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity.The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.High-content screening technology for studying drug-induced hepatotoxicity in cell models.Molecular biomarkers of phospholipidosis in rat blood and heart after amiodarone treatment.Amphiphilic drug interactions with model cellular membranes are influenced by lipid chain-melting temperature An Immunohistochemical Investigation of Renal Phospholipidosis and Toxicity in Rats.The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury.Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis.Occupational Asthma Due to Inhalation of Aerosolized Lipophilic Coating Materials.Toward a unifying strategy for the structure-based prediction of toxicological endpoints.Is It Adverse, Nonadverse, Adaptive, or Artifact?Renal phospholipidosis possibly induced by ranolazine.Differential cytotoxicity responses by dog and rat hepatocytes to phospholipogenic treatments.Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.Phospholipidosis induced by PPARγ signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone.

P2860

Q24635290-C5AFB423-D554-4F01-9225-A59F2A944C42 Q26766096-4845A8DD-6636-4D47-BA39-99C6CD936DCD Q28257881-59E4FC29-BAED-4480-80CF-9213EA2B4E93 Q28278771-B99BF6D8-972E-4267-A270-FB257E948151 Q30560958-0063B58A-432E-4146-98BA-763A609A9D21 Q30841407-815B387C-A55D-418A-B469-896F950224B3 Q33686976-3EB8DB24-8A38-42A4-9F7C-9DF8364F6965 Q33845886-F272F63A-2FAF-4AA1-AF57-A8E2AEDCD5AE Q33880158-38848714-6FD8-449A-B73B-625CCEDF5F82 Q33939074-B80A53E9-63E6-483D-9865-7E174E10996A Q34244280-3207AB38-10AB-4322-88E2-8DE22C7F0969 Q34596668-1EA0F094-1470-49F4-8732-45B0723C294D Q34726610-D5CEED36-3D24-4A26-85DB-E62E84C1E43A Q34977885-10C8D9EB-B1FD-4EF7-BA4D-86F7EF04B4A6 Q35827839-D3D1BAA5-8BEC-4D36-A6AA-2C4957C3FB6E Q36234390-B6861ABB-F4B9-4AD7-9E72-C6E0F182E9BE Q36609748-8F806AAF-515A-447B-BE4C-075C23B730B5 Q36667157-478DF389-215C-4D3B-873B-F4542F2302BB Q36985063-AF55102A-5504-4031-9D74-3155370B42CD Q37529605-EE08C31D-F615-4D90-BD9C-F811F0AB1649 Q37554404-0D3330E9-4EFC-475F-A6BF-D48E36C0EFDF Q37723945-538BC8CE-161B-43CE-8E7D-3F22D9A0CEC6 Q37824547-1CD86C5E-9598-494F-8579-C27BB699EA0D Q37829433-CFB22C95-5965-452C-9707-85B7A2C0DB36 Q37950014-57671B61-9A8D-4FB9-9B56-EA8D2C9E71FF Q37999093-3494B74C-40CB-4F8A-BBB1-500F77A034CE Q38383132-027E4614-AB80-4DC9-AE13-E43F5E34E82F Q38468007-047DD722-4501-45DA-BF6D-66031020CB36 Q38594358-85D88BF2-F6F2-4BF5-A805-90B5995D9447 Q38618764-E39EBB98-6D67-46A7-8EAC-CAC18914A748 Q38651282-83B3DAAE-2FAE-4BCD-AA0B-CB65C310F0A5 Q38732067-41F02041-E261-4DBC-B6F7-DE72AF9B4146 Q38793908-BB1F048B-5E4F-486C-BD24-08ED6D74229F Q38890510-DE9D4420-E45C-4C75-8CCE-E67161259BC9 Q38944440-8B62BF25-D3D9-4021-9D90-1319E010B222 Q39260081-232C7312-0723-40A8-A772-DAE99D62CCE0 Q39369271-6AD244A1-BA86-4CCA-99E4-623AF4B58D60 Q39374963-098E17DD-BAB8-423F-AA04-B1DD47C84F4A Q39541065-F7463EAF-42E2-403A-B0D1-A1A947BBF35F Q39625030-6DBBC39B-E382-481B-8985-4131CE2A835C

P2860

Drug-induced phospholipidosis: issues and future directions

http://www.wikidata.org/entity/Q28246047

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Drug-induced phospholipidosis: issues and future directions

@ast

Drug-induced phospholipidosis: issues and future directions

@en

Drug-induced phospholipidosis: issues and future directions

@nl

type

label

Drug-induced phospholipidosis: issues and future directions

@ast

Drug-induced phospholipidosis: issues and future directions

@en

Drug-induced phospholipidosis: issues and future directions

@nl

prefLabel

Drug-induced phospholipidosis: issues and future directions

@ast

Drug-induced phospholipidosis: issues and future directions

@en

Drug-induced phospholipidosis: issues and future directions

@nl

P1433

Q28246047-66E11436-54AA-48B2-9210-2CE5EA983DEE

P1476

Q28246047-64E73F53-C22E-4C12-AA37-E32259614A24

P2093

Q28246047-269B851B-1219-41AB-81C5-011392DC51E9

Q28246047-6A6B7DB8-0946-400A-9CF7-F1FABA87D935

Q28246047-8BB8FF25-49B7-4CE9-BDA2-8373CFD46082

P2860

Q28246047-0317BE18-B59C-457B-A6E6-0894F74539F3

Q28246047-03C2847C-68C6-40FA-A6DD-37C46F36DCB4

Q28246047-0FEE02CE-6D68-4870-AB8F-60468825983E

Q28246047-13D9112C-892F-41B7-9212-722677017229

Q28246047-1502E920-21DC-4499-A608-0305C947D50C

Q28246047-1901C906-76AE-40B8-88A5-80AF47FDE354

Q28246047-24C7B221-0B33-48C1-B4E4-9ECC33929BDD

Q28246047-265C1A2A-DEA0-47F6-8D4A-A6CD0371CBE7

Q28246047-28CB2AB7-26FB-4B32-AB8F-67C2A01B7FB1

Q28246047-28F9F9EA-1F61-4E4E-8341-9F4449007839

P304

Q28246047-0C35A412-CD5F-4B74-9AA4-9F0F2D7D5A61

P31

Q28246047-87A76F9B-E3ED-4BC3-86B6-6E92804172F3

P356

Q28246047-115C329E-5E5C-4A83-93A0-6B15000E1350

P407

Q28246047-F494A1BC-4FEB-4F87-995C-04F833905CD0

P433

Q28246047-BC40A613-ED58-408E-A8BB-1D5F963CDDC6

P478

Q28246047-89A1788D-372F-4192-9480-CC9C621FF132

P577

Q28246047-CC729F02-15FB-4168-8E8D-33A367FEF34F

P698

Q28246047-0A07E368-B4D2-4A5D-A439-B71A54EA3996

P356

14740338.5.4.567

P1433

Expert Opinion on Drug Safety

P1476

Drug-induced phospholipidosis: issues and future directions

@en

P2093

Kenneth L Hastings

http://www.w3.org/2001/XMLSchema#string

Mark J Reasor

http://www.w3.org/2001/XMLSchema#string

Roger G Ulrich

http://www.w3.org/2001/XMLSchema#string

P2860

Subchronic pulmonary inflammation and fibrosis induced by silica in rats are attenuated by amiodarone

Acute silica toxicity: attenuation by amiodarone-induced pulmonary phospholipidosis

Identification of putative gene based markers of renal toxicity

Neuropathy and fatal hepatitis in a patient receiving amiodarone

Endocytic recycling

Validation of an in vitro screen for phospholipidosis using a high-content biology platform.

Antidepressant-induced lipidosis with special reference to tricyclic compounds.

Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides.

Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes--an ultrastructural study.

Pulmonary changes induced by amphophilic drugs.

P304

567-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.5.4.567

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16774494

http://www.w3.org/2001/XMLSchema#string